Peter A. Jones, PhD, DSc
Research Director and Chief Scientific Officer, Van Andel Research Institute, Grand Rapids, Michigan
A pioneer in the field of epigenetics, Dr. Jones has uncovered basic mechanisms of DNA methylation and its role in cancer. He discovered that 5-azacytidine can induce changes in gene expression and act as a powerful DNA methylation inhibitor, which led to the isolation of the first mammalian determination gene and to the discovery of tumor suppressor genes that are epigenetically silenced in human cancer. The drug 5-azacytadine has been approved for use in treatment of myelodysplastic syndrome.
Dr. Jones’ collaborative research has led to delineating molecular pathways in the development of bladder cancer and to the realization that DNA methylation sites are hotspots for cancer-causing mutations and that epigenetic silencing plays a major role in carcinogenesis. He helped establish the International Human Epigenome consortium and co-directs a Stand-Up-to-Cancer dream team developing new cancer treatments.
2016 Elected Member, National Academy of Sciences2011 Medal of Honor, American Cancer Society2010 Elected Fellow, American Association for the Advancement of Science2009 AACR-Kirk A. Landon Prize for Basic Cancer Research2008 Oettle Award, Cancer Association of South Africa2008 David Workman Memorial Award, Samuel Waxman Cancer Research Foundation2005-2006 President, AACR2001 Simon M. Shubitz Award, University of Chicago Cancer Research Center1999 Distinguished Professor, USC1993-2011 Director, USC Norris Comprehensive Cancer Center1991-1994 Associate Dean for Academic and Scientific Affairs, USC School of Medicine1989-1992 Board of Directors, AACR1983 D.Sc., University of Zimbabwe1983 USC Associates Award for Creativity in Research and Scholarship1973 PhD, University of London